Priya Kishnani, MD, Chen Family Professor of Pediatrics, Chief of the Division of Medical Genetics, Duke University Medical Center, and Medical Director of the YT and Alice Chen Pediatric Genetic and Genomics Center, discusses clinical trial data of Sanofi’s avalglucosidase, a next-generation enzyme therapy with more efficient targeting to the skeletal muscle compared with standard-of-care therapy. There was an improvement in respiratory outcomes, mobility outcomes, and patient-reported measures with patients on avalglucosidase compared with standard-of-care therapy.